[{"id":"17a373bf-e674-4aa0-a914-22e6aff84f1c","acronym":"CIRCALL","url":"https://clinicaltrials.gov/study/NCT07483476","created_at":"2026-03-28T01:37:46.104Z","updated_at":"2026-03-28T01:37:46.104Z","phase":"","brief_title":"Study of Cell-free DNA in Children and Adolescents With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT07483476 - CIRCALL","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" ABL1 • KMT2A","pipe":" | ","alterations":" KMT2A rearrangement","tags":["ABL1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 205","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 07/01/2029","primary_completion_date":" 07/01/2029","study_txt":" Completion: 04/01/2034","study_completion_date":" 04/01/2034","last_update_posted":"2026-03-19"},{"id":"ae37ad26-112d-406e-b4ec-b9bd80c911c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292664","created_at":"2022-03-23T13:53:35.750Z","updated_at":"2025-02-25T14:08:44.222Z","phase":"Phase 1","brief_title":"Venetoclax Basket Trial for High Risk Hematologic Malignancies","source_id_and_acronym":"NCT05292664","lead_sponsor":"Andrew E. Place, MD","biomarkers":" FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1","pipe":" | ","alterations":" KMT2A rearrangement • ABL1 fusion","tags":["FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 07/02/2026","primary_completion_date":" 07/02/2026","study_txt":" Completion: 07/02/2028","study_completion_date":" 07/02/2028","last_update_posted":"2025-02-17"},{"id":"2215a379-2b74-4e43-b073-534f2995d428","acronym":"","url":"https://clinicaltrials.gov/study/NCT06001788","created_at":"2023-08-21T14:08:48.344Z","updated_at":"2025-02-25T15:13:42.778Z","phase":"Phase 1","brief_title":"Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06001788","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" FLT3 • NPM1 • KMT2A","pipe":" | ","alterations":" FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation","tags":["FLT3 • NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • NPM1 mutation • KMT2A rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • Komzifti (ziftomenib) • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 02/22/2024","start_date":" 02/22/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-13"},{"id":"52201742-0575-4575-a34b-9248823aad77","acronym":"APAL2020SC","url":"https://clinicaltrials.gov/study/NCT04726241","created_at":"2021-01-27T13:53:55.563Z","updated_at":"2025-02-25T15:11:53.004Z","phase":"Phase 1/2","brief_title":"The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia \u0026 Lymphoma Society and Children's Oncology Group Study","source_id_and_acronym":"NCT04726241 - APAL2020SC","lead_sponsor":"LLS PedAL Initiative, LLC","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 960","initiation":"Initiation: 04/18/2022","start_date":" 04/18/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"},{"id":"effe32d4-632d-47ed-9569-8f5ee71685a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05326516","created_at":"2022-04-13T11:55:14.906Z","updated_at":"2024-07-02T16:35:02.858Z","phase":"Phase 1","brief_title":"A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia","source_id_and_acronym":"NCT05326516","lead_sponsor":"Syndax Pharmaceuticals","biomarkers":" KMT2A • NUP98","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A • NUP98"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • cyclophosphamide • Revuforj (revumenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/09/2022","start_date":" 03/09/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-17"},{"id":"c62a7f73-b1c2-406a-b3bd-f74ccdc4bd18","acronym":"KOMET-007","url":"https://clinicaltrials.gov/study/NCT05735184","created_at":"2023-02-21T16:01:44.880Z","updated_at":"2024-07-02T16:35:03.357Z","phase":"Phase 1","brief_title":"A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML","source_id_and_acronym":"NCT05735184 - KOMET-007","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • daunorubicin • Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 212","initiation":"Initiation: 07/18/2023","start_date":" 07/18/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-05-16"},{"id":"77accf55-b1ad-4e14-aada-f3a5e55d16c9","acronym":"EU PIP Study","url":"https://clinicaltrials.gov/study/NCT05748171","created_at":"2023-02-28T13:01:32.364Z","updated_at":"2024-07-02T16:35:06.949Z","phase":"Phase 2","brief_title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to ","source_id_and_acronym":"NCT05748171 - EU PIP Study","lead_sponsor":"Pfizer","biomarkers":" TP53 • KMT2A • CD22 • TCF3 • PBX1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD22 positive","tags":["TP53 • KMT2A • CD22 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 07/11/2028","primary_completion_date":" 07/11/2028","study_txt":" Completion: 07/09/2031","study_completion_date":" 07/09/2031","last_update_posted":"2024-04-30"},{"id":"7c4b8485-206a-4268-adbf-1fdeb567ca5c","acronym":"Interfant-21","url":"https://clinicaltrials.gov/study/NCT05327894","created_at":"2022-04-14T11:53:34.155Z","updated_at":"2024-07-02T16:35:11.206Z","phase":"Phase 3","brief_title":"Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia","source_id_and_acronym":"NCT05327894 - Interfant-21","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab)"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2024-04-05"},{"id":"26556d3b-e333-41d1-a129-50ec08ae32ca","acronym":"AALL15P1","url":"https://clinicaltrials.gov/study/NCT02828358","created_at":"2021-07-12T20:53:08.460Z","updated_at":"2024-07-02T16:35:13.043Z","phase":"Phase 2","brief_title":"Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement","source_id_and_acronym":"NCT02828358 - AALL15P1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KMT2A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"6920805f-47cc-46c1-9b7c-1cf720663501","acronym":"KOMET-001","url":"https://clinicaltrials.gov/study/NCT04067336","created_at":"2021-01-17T17:22:51.063Z","updated_at":"2024-07-02T16:35:14.761Z","phase":"Phase 1/2","brief_title":"First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04067336 - KOMET-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Komzifti (ziftomenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 199","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-15"},{"id":"6c05718b-8a7f-4a20-bf78-b51f8a8735e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06052813","created_at":"2023-09-25T14:10:32.555Z","updated_at":"2024-07-02T16:35:18.364Z","phase":"Phase 1/2","brief_title":"A Study of BN104 in the Treatment of Acute Leukemia","source_id_and_acronym":"NCT06052813","lead_sponsor":"BioNova Pharmaceuticals (Shanghai) LTD.","biomarkers":" NPM1 • KMT2A","pipe":" | ","alterations":" NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation","tags":["NPM1 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/16/2023","start_date":" 09/16/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-21"},{"id":"a371a01d-3ae1-4151-8cf6-c3f5a72a47d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05507827","created_at":"2022-08-19T17:10:05.391Z","updated_at":"2024-07-02T16:35:18.561Z","phase":"Phase 1","brief_title":"Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT05507827","lead_sponsor":"Dr. Melody Smith, MD, MS","biomarkers":" CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement","tags":["CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orca-T • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 01/01/2037","primary_completion_date":" 01/01/2037","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2024-02-20"},{"id":"aab02437-3669-4686-b502-9402be6b93b0","acronym":"HAMLET","url":"https://clinicaltrials.gov/study/NCT03275636","created_at":"2021-01-18T16:10:38.865Z","updated_at":"2024-07-02T16:35:43.042Z","phase":"Phase 2/3","brief_title":"Haploidentical Donor vs mMUD in Hematological Malignancies","source_id_and_acronym":"NCT03275636 - HAMLET","lead_sponsor":"DKMS gemeinnützige GmbH","biomarkers":" ABL1 • BCR • KMT2A • HLA-DRB1 • HLA-B • HLA-C","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-07-13"},{"id":"f51c3ecd-a431-4fc0-8ad8-bef6f1f0a08c","acronym":"T-allo10","url":"https://clinicaltrials.gov/study/NCT03198234","created_at":"2021-01-18T15:46:13.978Z","updated_at":"2024-07-02T16:35:51.038Z","phase":"Phase 1","brief_title":"Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders","source_id_and_acronym":"NCT03198234 - T-allo10","lead_sponsor":"Roncarolo, Maria Grazia, MD","biomarkers":" KMT2A • NUP98 • CBFA2T3 • GLIS2 • KDM5A","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["KMT2A • NUP98 • CBFA2T3 • GLIS2 • KDM5A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/30/2017","start_date":" 08/30/2017","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-04-10"}]